Class / Patent application number | Description | Number of patent applications / Date published |
514700800 | Thrombopoietin (TPO) or derivative | 9 |
20110071077 | Thrombopoietic Compounds - The invention relates to the use of compounds, especially peptides or polypeptides, that have thrombopoietic activity, and pegylated forms thereof. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 03-24-2011 |
20110160130 | CANCER TREATMENT METHOD - Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a combination of a non-peptide TPO receptor agonist or a peptide TPO mimetic and a cell cycle signalling inhibitor compound to such mammal. | 06-30-2011 |
20110218144 | Method of Reducing Deleterious Effects of Ischemia-Reperfusion - A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The thrombopoietin is administered in a concentration such that the subject's platelet count or production of platelets is not significantly affected. | 09-08-2011 |
20110288019 | METHODS OF INCREASING PLATELET AND HEMATOPOIETIC STEM CELL PRODUCTION - A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed. | 11-24-2011 |
20110294733 | MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND MANUFACTURING METHOD THEREOF - The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans. | 12-01-2011 |
20120094907 | PEPTIDE THERAPY FOR INCREASING PLATELET LEVELS - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis. | 04-19-2012 |
20130210724 | Cyclodextrin-Based Polymers for Therapeutic Delivery - Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. | 08-15-2013 |
20140051631 | PHARMACEUTICAL COMPOSITION COMPRISING TPO OR AN AGONIST OF THE TPO RECEPTOR - The present invention relates to a new use of TPO or a TPO/mpl receptor agonist as an adjuvant of a treatment of a neoplastic disease by irradiation or chemotherapeutic agents in order to prevent genomic instability of hematopoietic stem cells incurred through radio- or chemotherapy and hence to prevent the occurrence of secondary cancers, namely acute myelogenous leukemia and myelodisplasia. | 02-20-2014 |
20160067301 | ANTAGONISM OF ABCG4, LYN KINASE, AND C-CBL E3 LIGASE TO INCREASE PLATELET COUNT AS THERAPY FOR THROMBOCYTOPENIA - The present invention provides a method of treating a subject to increase the subject's platelet count which comprises administering to the subject an amount of one or more of an antagonist or inhibitor of ABCG4, Lyn kinase or c-CBL effective to antagonize or inhibit such ABCG4, Lyn kinase or c-CBL so as to thereby increase the subject's platelet count. | 03-10-2016 |